It seemed that the article suggested to "combine" Remdesivir with Brilacidin. The comment below supports this:
A desirable outcome for any potential COVID-19 therapeutic will be its ability to synergize with existing COVID-19 treatments, particularly if the mechanisms of action of the synergistic treatments can impact more than one step of the viral lifecycle.
Seems a little "political" to me....just curious wouldn't Gilead Sciences want to partner with IPIX because of this?
Market Data 
Markets 
AI
